Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18

Benzinga · 2d ago
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and lowers the price target from $19 to $18.